Cancer immunotherapy trials in China?

It's unclear whether there's any substance behind this. The company seems a bit sketchy but, as his bio below shows, Dr. Daopei Lu is certainly a distinguished member of the medical community.

Generex Biotechnology Corporation (GNBT) announced it would stage the Phase I trial of its cancer immunotherapy in China. The trial will be performed in collaboration with Dr. Daopei Lu and the Beijing Daopei Hospital in Beijing, China. Dr. Lu, a hematologist-oncologist, has conducted many clinical trials and authored over 200 articles in peer-review journals.




Dr. Lu simultanously acts as a vice president of the Chinese Medical Association, chairman of the Society of Hematological Malignancies, Chinese Anti-Cancer Association and a member of the Advisory Committee of international Bone Marrow Transplantation Registry. In addition, he is also editor in chief, deputy editor in chief or editor for eight domestic medical journals and an editorial member of two international journals.